The company expects an operating loss of USD 230 million in the second quarter and an operating loss of USD 200-300 million for the year as a whole.
Revenue for 2025 is now estimated at USD 12.0-12.2 billion
Medical loss ratio increases to 86-87% due to continued high risk assessments and high utilization. Adjusted EBITDA loss is expected to be approximately USD 120 million lower than the operating loss. The full report will be published pre-market on August 6
https://www.tradingview.com/news/DJN_DN20250722001515:0/
